Valeant to acquire OraPharma in $312 million deal
MONTREAL — Valeant Pharmaceuticals International has agreed to acquire a specialty oral health company that develops and commercializes products that improve and maintain oral health.
Valeant said it is acquiring OraPharma from private equity firm Water Street Healthcare Partners for $312 million. The drug maker also said it will pay $114 million in potential contingent payments based on certain milestones.
"We are excited to enter a new attractive market segment with an already established sales infrastructure focused entirely on the dental community," Valeant chairman and CEO J. Michael Pearson said. "We believe that this market segment has similar characteristics to the dermatology, podiatry and ophthalmology markets and should offer us the opportunity to cross-sell some of our current products, most notably our new topical prescription cold sore medication, Xerese. We believe the OraPharma business is a new growth platform from which to build additional opportunities in the future."
No comments found
FDA approves MenHibrix
PHILADELPHIA — GlaxoSmithKline has received regulatory approval from the Food and Drug Administration for a vaccine designed to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type B.
MenHibrix (Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid conjugate vaccine) is approved for use in children ages six weeks through 18 months. The vaccination schedule is a four-dose series given at two, four, six, and 12 through 15 months of age.
"All of us at GSK vaccines look at today’s approval as a good day for infants, toddlers and healthcare providers," said Leonard Friedland, VP and head of clinical and medical affairs of North America vaccine development for GSK Vaccines. "MenHibrix gives healthcare providers the option of combining Hib immunization with meningococcal C and Y immunization without increasing the number of shots for infants and toddlers."
In September 2011, the FDA declined to approve the drug and sent GSK a complete response letter.
No comments found
Suave Professionals, Univision debut consumer walk-on role on a telenovela
NEW YORK — Unilever’s Suave Professionals hair care brand and Univision took their partnership to the next level and gave one beauty maven the chance to star in a telenovela.
As the official hair care sponsor of "El Talisman," Suave Professionals offered one fan the opportunity to win a walk-on role. "For 50 years, Suave has made beautiful hair accessible to all women by providing salon-quality products and benefits at a reasonable price. Our partnership with Univision and ‘El Talisman’ takes that promise another step further, making TV stardom possible for one lucky consumer," stated David Rubin, U.S. hair care marketing director for Unilever. "We provided a one-of-a-kind opportunity to bring Latinas closer to their favorite novela stars, and for the first time put a fan on the show."
The "Estrena Tu Transformacion" (Reveal Your Transformation) contest tasked consumers with sharing their most dramatic hair transformations on Suave’s Spanish-language Facebook page, Belleza Suave, for the chance to make their grand debut on the telenovela, receive a makeover by Suave Professionals celebrity stylist Leonardo Rocco and win $5,000 cash prize. The grand prize winner was Mayra Mendoza.
Taking the integration a step further, a dedicated section on NovelasySeries.com featured Talisman-inspired hairstyle how-to videos, recreated by Rocco. Throughout the telenovela, the Suave Professionals Keratin Infusion range was integrated into three pivotal moments of the story. One of these moments included a wedding scene where the contest grand prize winner, Mendoza, starred in.
The telenovela will culminate with Mendoza’s scene, where she plays Carmen and exchanges an emotional encounter with a key character in a climactic scene in the episode.